Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation
- PMID: 16951223
- PMCID: PMC2692690
- DOI: 10.1158/1078-0432.CCR-06-0196
Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation
Abstract
Purpose: We have shown recently that glycogen synthase kinase-3 (GSK-3) beta regulates nuclear factor-kappaB (NF-kappaB)-mediated pancreatic cancer cell survival and proliferation in vitro. Our objective was to determine the localization of GSK-3beta in pancreatic cancer cells and assess the antitumor effect of GSK-3 inhibition in vivo to improve our understanding of the mechanism by which GSK-3beta affects NF-kappaB activity in pancreatic cancer.
Experimental design: Immunohistochemistry and cytosolic/nuclear fractionation were done to determine the localization of GSK-3beta in human pancreatic tumors. We studied the effect of GSK-3 inhibition on tumor growth, cancer cell proliferation, and survival in established CAPAN2 tumor xenografts using a tumor regrowth delay assay, Western blotting, bromodeoxyuridine incorporation, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.
Results: We found nuclear accumulation of GSK-3beta in pancreatic cancer cell lines and in 62 of 122 (51%) human pancreatic adenocarcinomas. GSK-3beta nuclear accumulation is significantly correlated with human pancreatic cancer dedifferentiation. We have found that active GSK-3beta can accumulate in the nucleus of pancreatic cancer cells and that inhibition of GSK-3 kinase activity represses its nuclear accumulation via proteasomal degradation within the nucleus. Lastly, we have found that inhibition of GSK-3 arrests pancreatic tumor growth in vivo and decreases NF-kappaB-mediated pancreatic cancer cell survival and proliferation in established tumor xenografts.
Conclusions: Our results show the antitumor effect of GSK-3 inhibition in vivo, identify GSK-3beta nuclear accumulation as a hallmark of poorly differentiated pancreatic adenocarcinoma, and provide new insight into the mechanism by which GSK-3beta regulates NF-kappaB activity in pancreatic cancer.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2692690/bin/nihms15804f1.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2692690/bin/nihms15804f2.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2692690/bin/nihms15804f3.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2692690/bin/nihms15804f4.gif)
Similar articles
-
Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells.Cancer Res. 2005 Mar 15;65(6):2076-81. doi: 10.1158/0008-5472.CAN-04-3642. Cancer Res. 2005. PMID: 15781615
-
Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.Cancer Res. 2008 Oct 1;68(19):8156-63. doi: 10.1158/0008-5472.CAN-08-1061. Cancer Res. 2008. PMID: 18829575 Free PMC article.
-
Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.J Natl Cancer Inst. 2012 May 16;104(10):749-63. doi: 10.1093/jnci/djs210. Epub 2012 Apr 24. J Natl Cancer Inst. 2012. PMID: 22534782 Free PMC article.
-
The role of glycogen synthase kinase-3beta in normal haematopoiesis, angiogenesis and leukaemia.Curr Med Chem. 2008;15(15):1493-9. doi: 10.2174/092986708784638834. Curr Med Chem. 2008. PMID: 18537625 Review.
-
Primers on molecular pathways. The glycogen synthase kinase-3beta.Pancreatology. 2007;7(5-6):398-402. doi: 10.1159/000108955. Epub 2007 Oct 1. Pancreatology. 2007. PMID: 17912008 Free PMC article. Review.
Cited by
-
Multi-signal regulation of the GSK-3β homolog Rim11 controls meiosis entry in budding yeast.EMBO J. 2024 Aug;43(15):3256-3286. doi: 10.1038/s44318-024-00149-7. Epub 2024 Jun 17. EMBO J. 2024. PMID: 38886580 Free PMC article.
-
The many faceted role of glycogen synthase kinase-3 (GSK-3) in T cells and cancer immunotherapy.J Cancer Biol. 2024;5(1):11-16. doi: 10.46439/cancerbiology.5.058. J Cancer Biol. 2024. PMID: 38813058 Free PMC article. No abstract available.
-
Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma.Cancer Sci. 2024 Apr;115(4):1333-1345. doi: 10.1111/cas.16100. Epub 2024 Feb 6. Cancer Sci. 2024. PMID: 38320747 Free PMC article.
-
Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer.Cancer Drug Resist. 2024 Jan 31;7:4. doi: 10.20517/cdr.2023.84. eCollection 2024. Cancer Drug Resist. 2024. PMID: 38318525 Free PMC article. Review.
-
Characterization of neuroendocrine regulation- and metabolism-associated molecular features and prognostic indicators with aid to clinical chemotherapy and immunotherapy of patients with pancreatic cancer.Front Endocrinol (Lausanne). 2023 Jan 20;13:1078424. doi: 10.3389/fendo.2022.1078424. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36743929 Free PMC article.
References
-
- Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κBRelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119–27. - PubMed
-
- Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell. 2004;6:203–8. - PubMed
-
- Wang CY, Cusack JC, Jr, Liu R, Baldwin AS., Jr Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med. 1999;5:412–7. - PubMed
-
- Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta. 1992;1114:147–62. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous